BioSpace News Archive

Dômes Pharma announces that it has finalized the acquisition of SentrX Animal Care, a US company based in Salt Lake City. SentrX develops and manufactures ophthalmology products based on its exclusive BioHAnce™ technology.

Nevro Corp. today announced the publication of 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN, in Diabetes Research and Clinical Practice.

Oncoclínicas Group generated record earnings in the second quarter of 2023, R$309 million and a net profit of R$35 million.

Vivos Therapeutics, Inc. today announced that the Company intends to release its second quarter 2023 financial results after market close today, Wednesday, August 16, 2023.

Entera Bio Ltd. today announced that it has been selected to present data for its investigational agent EB613 at the ASBMR 2023 Annual Meeting on October 13-16, 2023 in Vancouver, BC, Canada.

Napo Pharmaceuticals, Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of a Napo-sponsored survey of 15 US neurologists who treat patients with amyotrophic lateral sclerosis (ALS), and the results of a corresponding Napo-sponsored survey of 15 US individuals who are either ALS patients or caregivers of an ALS patient.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions.

The National Comprehensive Cancer Network® announced that a library of resources for improving cancer care in the Middle East and North Africa has been updated and expanded in collaboration with regional experts.

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis has been selected for oral presentation at the 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023.

EV Biologics Corp, OTC PINK:YECO, announced that it has completed production of a next-generation, “Gen-2", MSC exosome-based therapeutic product.